Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Given the strong link between use of unopposed estrogens and development of endometrial cancers, estrogens are usually prescribed with a progestin, particularly for women with intact uteri. Some studies suggest that sequential use of progestins may increase risk; however, the moderating effects of usage patterns or patient characteristics, including body mass index (BMI), are unknown. We evaluated menopausal hormone use and incident endometrial cancer (n = 885) in 68,419 postmenopausal women with intact uteri enrolled in the National Institutes of Health‐American Association of Retired Persons Diet and Health study. Participants completed a risk factor questionnaire in 1996–1997 and were followed up through 2006. Hazard rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Cox regression. Among 19,131 women reporting exclusive estrogen plus progestin use, 176 developed endometrial cancer (RR = 0.88; 95% CI = 0.74–1.06). Long‐duration (≥10 years) sequential (<15 days progestin per month) estrogen plus progestin use was positively associated with risk (RR = 1.88; 95% CI = 1.36–2.60], whereas continuous (>25 days progestin per month) estrogen plus progestin use was associated with a decreased risk (RR = 0.64; 95% CI = 0.49–0.83). Increased risk for sequential estrogen plus progestin was seen only among thin‐to‐normal weight women (BMI < 25 kg/m 2; RR = 2.53). Our findings support that specific categories of estrogen plus progestin use increases endometrial cancer risk, specifically long durations of sequential progestins, whereas decreased endometrial cancer risk was observed for users of short‐duration continuous progestins. Risks were highest among thin‐to‐normal weight women, presumably reflecting their lower endogenous estrogen levels, suggesting that menopausal hormones and obesity increase endometrial cancer through common etiologic pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Source of Estrogen Production in Postmenopausal Women1
GRODIN, J. M., SIITERI, P. K., & MACDONALD, P. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-2-207 · Cited by 959
Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis
Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M., & Renehan, A. G. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0832 · Cited by 321
Lukanova, A., Lundin, E., Zeleniuch-Jacquotte, A., Muti, P., Mure, A., Rinaldi, S., Dossus, L., Micheli, A., Arslan, A., Lenner, P., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500161 · Cited by 315 · cited 1×
“Obese women have three to five times the risk of endometrial cancer compared to women of normal weight,(6,16) reportedly reflecting increased conversion of androgens to estrogens and higher circulating estradiol concentrations.(17) The effects of unopposed estrogens on endometrial cancer risk have been shown to be mod…”
Background
Research works printed but not linked: 29
- Reis L, 2010, SEER Cancer Statistics Review, 1975–2005
- 10.1056/NEJM197512042932302 · DOI · Paper page
- 10.1056/NEJM197512042932303 · DOI · Paper page
- 10.1016/0029-7844(94)00383-O · DOI · Paper page
- 10.1158/1055-9965.EPI-05-0111 · DOI · Paper page
- 10.1097/AOG.0b013e3181bea950 · DOI
- 10.1002/ijc.24672 · DOI
- 10.1093/aje/kwq300 · DOI · Paper page
- 10.1093/jnci/89.15.1110 · DOI · Paper page
- 10.1093/jnci/91.13.1131 · DOI · Paper page
- 10.1023/A:1023066304473 · DOI
- 10.1016/j.ajog.2007.01.019 · DOI
- 10.1158/1055-9965.EPI-09-0712 · DOI
- 10.1002/cncr.22525 · doi:10.1002/cncr.22525
- 10.1158/1055-9965.EPI-06-0675 · DOI · Paper page
- 10.1093/aje/154.12.1119 · DOI · Paper page
- 10.1001/jama.288.3.321 · DOI · Paper page
- 10.1016/S0895-4356(99)00192-4 · doi:10.1016/s0895-4356(99)00192-4
- Whitehead MI, 1987, The effects of estrogens and progestogens on the endometrium. Modern approach to treatment, Obstet Gynecol Clin North Am, 14, 299, 10.1016/S0889-8545(21)00584-2 · doi:10.1016/s0889-8545(21)00584-2
- 10.1093/aje/kwj316 · DOI
- 10.1007/s10552-011-9840-6 · doi:10.1007/s10552-011-9840-6
- 10.1007/s10552-006-0113-8 · DOI · Paper page
- 10.1007/s10552-010-9568-8 · DOI
- 10.1158/1055-9965.EPI-07-2567 · DOI · Paper page
- 10.1016/S0140-6736(05)66455-0 · DOI · Paper page
- 10.1016/j.annepidem.2011.01.003 · DOI
- 10.1080/13595220152601837 · doi:10.1080/13595220152601837
- 10.1016/S1047-2797(00)00186-1 · doi:10.1016/s1047-2797(00)00186-1
- 10.1038/oby.2007.504 · DOI · Paper page
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“tional studies suggest a potentially increased risk of endometrial cancer with cyclic progestogen regimens compared with continuous progestogen use and with the use of MP compared with other progestogens.(3,4,302) In the WHI, women with a uterus receiving EPT had a lower risk of endometrial cancer than women randomize…”
Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women
Clarke, M. A., Long, B. J., Del Mar Morillo, A., Arbyn, M., Bakkum-Gamez, J. N., & Wentzensen, N. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.2820 · Cited by 426
Self-citationRecent changes in endometrial cancer trends among menopausal-age US women.
Wartko, P., Sherman, M. E., Yang, H. P., Felix, A. S., Brinton, L. A., & Trabert, B. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.03.008 · Cited by 98
“In contrast, continuous regimen estrogen plus progestin MHT (26 days or more of progestin per month) is associated with a decreased endometrial cancer risk relative to non-hormone use [4].”
BackgroundSelf-citation
Metadata
- Authors
- Trabert, B., Wentzensen, N., Yang, H. P., Sherman, M. E., Hollenbeck, A. R., Park, Y., & Brinton, L. A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-08-30
- Volume
- 132
- Issue
- 2
- Pages
- 417-426
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2091303521
- Cited by
- 71
- References
- 5
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? https://app.cochat.ai/papers/10.1002/ijc.27623
- The paper
- Trabert, B., Wentzensen, N., Yang, H. P., Sherman, M. E., Hollenbeck, A. R., Park, Y., & Brinton, L. A. (2013). Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? International Journal of Cancer. https://doi.org/10.1002/ijc.27623
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.